These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 3655005)

  • 41. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
    Sarpatwari A; Beall RF; Abdurrob A; He M; Kesselheim AS
    Health Aff (Millwood); 2018 May; 37(5):732-737. PubMed ID: 29733729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Orphan drug product regulation--United States.
    Haffner ME
    Int J Clin Pharmacol Ther; 2002 Feb; 40(2):84-8. PubMed ID: 11862977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The year's new drugs & biologics, 2011.
    Graul AI; Cruces E; Dulsat C; Arias E; Stringer M
    Drugs Today (Barc); 2012 Jan; 48(1):33-77. PubMed ID: 22384459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Status and thoughts of Chinese patent medicines seeking approval in the US market.
    Lei X; Chen J; Liu CX; Lin J; Lou J; Shang HC
    Chin J Integr Med; 2014 Jun; 20(6):403-8. PubMed ID: 24952167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications.
    Camp JR; Fuhs JV; Beattie SD; Asay RL; Hoffman RD
    Ther Innov Regul Sci; 2021 May; 55(3):568-582. PubMed ID: 33492633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019-2023) by US FDA, best practices and recommendations.
    Mitra A; Lee JB; Steinbach D; Hazra A; Krishna R
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):475-493. PubMed ID: 37925369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2007 FDA drug approvals: a year of flux.
    Hughes B
    Nat Rev Drug Discov; 2008 Feb; 7(2):107-9. PubMed ID: 18246607
    [No Abstract]   [Full Text] [Related]  

  • 59. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.